MBX Biosciences to Participate in Upcoming November Investor Conferences
Globe Newswire•13/10/2026•08:00 ET
0
Key Highlights
- ➤MBX executives to present at three November investor conferences
- ➤Canvuparatide (MBX 2109) is in Phase 3 for chronic hypoparathyroidism
- ➤MBX 4291 is in Phase 1 for obesity
- ➤MBX 5765 and MBX 6180 remain in preclinical obesity development
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026 Format: Fireside Chat and 1x1 meetings Time: 11:00 – 11:25 a.m. EST Location: Boston, MA
Get started
Create a free account to read the full story.